

*Blue text are programmer notes. These are not translated and will not show on the webpage or email. Do not delete.*

*Content may include any images from the accompanying image library. The image library will be submitted separately for IRB review and approval. Please refer to the IRB-approved image library for the version number and date currently in use.*

*Content may also utilize study and Pfizer logos as necessary, as well as any advocacy partner branding or logos, such as but not limited to Unite4Her, FORCE, and Sisters Network:*



## Tile Card

### KATSIS-1

#### Pfizer Study #C4551002

- KATSIS-1 is a clinical trial evaluating prifetrastat in combination with fulvestrant, compared with 1 of 2 currently approved treatments (either exemestane or fulvestrant) chosen by the study doctor, plus an approved medicine called everolimus, for patients with advanced or metastatic breast cancer.
- The study population includes adults (women and men) with hormone receptor-positive (HR+), HER2-negative advanced breast cancer.
- Participants have received certain 2 or less previous treatments for their advanced or metastatic breast cancer, as well as treatment with a CDK4/6 inhibitor, such as palbociclib (Ibrance®), ribociclib (Kisqali®), or abemaciclib (Verzenio®)
- The study is currently open at about 48 sites across the United States, with hundreds of other sites open globally.
- If you or a loved one is interested in participating, please visit the study website for more details.
- **CTA BUTTON:** Learn More
- **LINK:**  
<https://www.katsis1study.com?cmp=fb424052-d8b8-49c1-9cf3-bab9821f6ba8&ttype=WEB>

## Newsletter

**Subject line: Redefining What's Possible to Advance Metastatic Breast Cancer Care**

### Body copy

KATSIS-1 is a clinical trial exploring an investigational medicine called prifetrastat. Over time, breast cancer cells can learn how to avoid standard hormone treatments and continue growing. Think of the cancer like a machine that has found a hidden workaround to keep running. Prifetrastat is designed to block that workaround and "rewire" the cells, making the cancer weak to standard hormone therapies once again. If your HR+, HER2- advanced or metastatic breast cancer has worsened after previous treatment or stopped responding to treatment, you may be eligible for KATSIS-1. To learn more about study participation and eligibility, please visit [www.katsis1study.com](http://www.katsis1study.com).

### Link:

[www.pfizerclinicaltrials.com/nct07062965-breast-cancer-trial?cmp2=ZP6K&cmp=74752e93-8b3e-421e-a49e-9bafdc7e8ac5&ttype=EM](http://www.pfizerclinicaltrials.com/nct07062965-breast-cancer-trial?cmp2=ZP6K&cmp=74752e93-8b3e-421e-a49e-9bafdc7e8ac5&ttype=EM)

## Social Media Posts

### Long format

The KATSIS-1 phase 3 clinical trial is investigating a potential treatment designed to block breast cancer cells from growing and surviving. Rather than being based on a specific test result, this treatment may work by interfering with how the cancer cells function. Learn more and see if you may qualify for participation.

### Link:

[www.pfizerclinicaltrials.com/nct07062965-breast-cancer-trial?cmp2=NIQW&cmp=7fe818ba-e5b7-41c3-9814-ee74306f4250&ttype=MM](http://www.pfizerclinicaltrials.com/nct07062965-breast-cancer-trial?cmp2=NIQW&cmp=7fe818ba-e5b7-41c3-9814-ee74306f4250&ttype=MM)

### Short format

KATSIS-1 is studying an investigational approach for HR-positive, HER2-negative advanced or metastatic breast cancer to see if tumors may respond again to standard endocrine (hormone) therapy—and potentially delay the need for chemotherapy. Learn more: [www.katsis1study.com](http://www.katsis1study.com)

**Link:**


[www.pfizerclinicaltrials.com/nct07062965-breast-cancer-trial?cmp2=JUWW&cmp=9f3cf813-8fcd-4051-a4ab-e887d6737278&ttype=MM](http://www.pfizerclinicaltrials.com/nct07062965-breast-cancer-trial?cmp2=JUWW&cmp=9f3cf813-8fcd-4051-a4ab-e887d6737278&ttype=MM)

**Imagery**



**Link:**

[www.pfizerclinicaltrials.com/nct07062965-breast-cancer-trial?cmp2=RXTA&cmp=fbdc9dfa-b7e1-4516-82ad-60c7922eb95e&ttype=WEB](http://www.pfizerclinicaltrials.com/nct07062965-breast-cancer-trial?cmp2=RXTA&cmp=fbdc9dfa-b7e1-4516-82ad-60c7922eb95e&ttype=WEB)



The advertisement features a photograph of two women, one with curly grey hair and one with dark hair, both smiling warmly. The Pfizer logo is in the top right corner. The text 'For people with metastatic breast cancer' is centered in green and white. Below it, a smaller white text reads: 'If you've already tried other therapies for your breast cancer, consider a clinical trial.' The Katsis-1 logo is in the bottom left corner.

**For people with  
metastatic breast cancer**

If you've already tried other therapies for your breast cancer, consider a clinical trial.

**Katsis-1**

**Link:**

[www.pfizerclinicaltrials.com/nct07062965-breast-cancer-trial?cmp2=2KWM&cmp=a7e83d92-ed85-41c8-aca1-c0bc48143c47&ttype=WEB](http://www.pfizerclinicaltrials.com/nct07062965-breast-cancer-trial?cmp2=2KWM&cmp=a7e83d92-ed85-41c8-aca1-c0bc48143c47&ttype=WEB)



Link:

[www.pfizerclinicaltrials.com/nct07062965-breast-cancer-trial?cmp2=I9WE&cmp=0adef0d8-cbdb-4f10-9f2e-d6c8f0d41e0e&ttype=MM](http://www.pfizerclinicaltrials.com/nct07062965-breast-cancer-trial?cmp2=I9WE&cmp=0adef0d8-cbdb-4f10-9f2e-d6c8f0d41e0e&ttype=MM)



Link:

[www.pfizerclinicaltrials.com/nct07062965-breast-cancer-trial?cmp2=IW03&cmp=2d260b02-0ded-4a1c-8620-292de4636c58&ttype=MM](http://www.pfizerclinicaltrials.com/nct07062965-breast-cancer-trial?cmp2=IW03&cmp=2d260b02-0ded-4a1c-8620-292de4636c58&ttype=MM)